A novel DSIP fusion protein reduced sleep latency and prolonged sleep duration in a mouse model of pentobarbital-induced sleep.
Background
Sleep is a fundamental biological process, and its disruption in the form of insomnia is a widespread issue. Delta sleep-inducing peptide (DSIP) is a naturally occurring nonapeptide known to promote slow-wave sleep. However, its therapeutic potential has been limited, and its direct pharmacological effects on insomnia remain poorly understood. Standard peptides often suffer from poor bioavailability and short half-lives, hindering their clinical application. To overcome these limitations, researchers are exploring protein fusion strategies to enhance stability and delivery, potentially unlocking the therapeutic value of peptides like DSIP for sleep disorders.
Study Design
Researchers engineered a fusion protein named PHD, consisting of a N-terminal TAT protein transduction domain, human serum albumin (HSA), and Delta Sleep-Inducing Peptide (DSIP). This PHD protein was expressed in Pichia pastoris and purified. To assess its pharmacological activity, mice were given single subcutaneous injections of PHD fusion protein at doses of 0.5, 1, or 2 mg/kg, or a vehicle control. The hypnotic effects were then evaluated using a classic pentobarbital-induced sleep test, with sleep latency and sleep duration as the primary endpoints.
Results
The PHD fusion protein significantly enhanced the hypnotic effects of pentobarbital in a dose-dependent manner. Increasing concentrations of the fusion protein led to a statistically significant (P<0.05) reduction in sleep latency and a prolongation of total sleep duration. Furthermore, the PHD protein dose-dependently induced mice to re-enter sleep after waking. The higher doses of 1.0 mg/kg and 2.0 mg/kg were particularly effective at this secondary endpoint.
Higher doses of PHD fusion protein (1.0, 2.0 mg/kg) significantly increased the rate of sleep re-onset compared with the vehicle group of mice (P<0.05).
This demonstrates that the engineered peptide not only helps initiate sleep but also helps maintain it. The successful expression and purification of the PHD protein to near homogeneity using DEAE Sepharose FF, Phenyl Sepharose HP, and Blue Sepharose 6 FF confirmed the viability of the production method.
Key Findings
- A novel fusion protein (PHD) containing DSIP, human serum albumin, and a TAT domain was successfully expressed and purified.
- PHD fusion protein dose-dependently reduced sleep latency in a pentobarbital-induced sleep test in mice (P<0.05).
- The fusion protein significantly prolonged sleep duration in mice co-administered with pentobarbital (P<0.05).
- Higher doses (1.0 and 2.0 mg/kg) of PHD significantly increased the rate of sleep re-onset compared to the vehicle group (P<0.05).
Why It Matters
This study presents a proof-of-concept for enhancing the therapeutic properties of DSIP through protein fusion engineering. By combining DSIP with human serum albumin and a protein transduction domain, the researchers created a molecule with improved pharmacological activity in an animal model. For individuals exploring sleep-promoting peptides, this suggests that modified forms of DSIP may offer more potent and reliable effects than the native peptide. This research is an early preclinical step, and human trials are needed to confirm safety, efficacy, and appropriate dosing. However, the PHD fusion protein represents a promising new drug candidate for insomnia, potentially leading to more effective peptide-based sleep aids that can overcome the typical limitations of short peptide half-life.
TitrateLab articles covering DSIP
Written by TitrateLab, separately from the study summarized above.
dsip
insomnia
sleep
peptide
animal study
neurological
